ArticleVaccine2007
Effect of adjuvants and route of immunizations on the immune response to recombinant plague antigens.
Article in Vaccine, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 49 citations in OpenAlex.
- From Bench to Field: A Guide to Formulating and Evaluating Anti-Tick Vaccines Delving beyond Efficacy to Effectiveness.Vaccines · 2021Review
- Prophylactic Multi-Subunit Vaccine againstVaccines · 2021Article
- Review
- Single-dose combination nanovaccine induces both rapid and long-lived protection against pneumonic plague.Acta biomaterialia · 2019Article
- The Mucosal Vaccine Adjuvant LT(R192G/L211A) or dmLT.mSphere · 2018Review
- Nasal aluminum (oxy)hydroxide enables adsorbed antigens to induce specific systemic and mucosal immune responses.Human vaccines & immunotherapeutics · 2017Article
- A live attenuated Salmonella Enteritidis secreting detoxified heat labile toxin enhances mucosal immunity and confers protection against wild-type challenge in chickens.Veterinary research · 2016Article
- Cationic liposome-hyaluronic acid hybrid nanoparticles for intranasal vaccination with subunit antigens.Journal of controlled release : official journal of the Controlled Release Society · 2015Article
- Article
- Sublingual immunotherapy: World Allergy Organization position paper 2013 update.The World Allergy Organization journal · 2014Article
- The A subunit of Escherichia coli heat-labile enterotoxin functions as a mucosal adjuvant and promotes IgG2a, IgA, and Th17 responses to vaccine antigens.Infection and immunity · 2012Article
- Plague: Infections of Companion Animals and Opportunities for Intervention.Animals : an open access journal from MDPI · 2011Review
- Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant.Clinical and vaccine immunology : CVI · 2011Article
- Purification and characterization of Yersinia enterocolitica and Yersinia pestis LcrV-cholera toxin A(2)/B chimeras.Protein expression and purification · 2010Article
- Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents.British journal of pharmacology · 2010Review
- Efficacy and safety of a modified vaccinia Ankara (MVA) vectored plague vaccine in mice.Vaccine · 2010Article
- Vaccine development in Staphylococcus aureus: taking the biofilm phenotype into consideration.FEMS immunology and medical microbiology · 2010Review
- Prophylactic administration of bacterially derived immunomodulators improves the outcome of influenza virus infection in a murine model.Journal of virology · 2010Article
- Model systems to study plague pathogenesis and develop new therapeutics.Frontiers in microbiology · 2010Article
- Technical transformation of biodefense vaccines.Vaccine · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
In this study, we compare four different adjuvants, LT(R192G), CpG ODN, MPL((R))TDM, and alum, for their ability to affect the magnitude, distribution, and duration of antibody responses against F1-V, the lead-candidate antigen for the next generation vaccine against plague, in a murine model. In addition, three different routes of immunization-intranasal (IN), transcutaneous (TC), and subcutaneous (SC) were compared with each adjuvant. Since aerosol exposure to biological warfare agents is of primary concern, both serum and bronchioalveolar lavage (BAL) were analyzed for antigen-specific antibody responses. The most significant findings of the study reported here are that (1) the adjuvant influences the Type 1/Type 2 balance of the antibody response in both the serum and BAL, (2) mucosal immunization is not necessary to obtain F1-V-specific BAL responses, (3) non-traditional adjuvants such as LT(R192G) work when delivered subcutaneously, (4) the route of immunization affects the magnitude of the immune response, and (5) F1-V is highly immunogenic by some routes even in the absence of an exogenously applied adjuvant. These studies provide important insights into the influence of different classes of adjuvants on the immune outcome in biodefense vaccines and for development of new-generation vaccines against other pathogens as well.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.